Passage Bio holds special stockholder meeting
PASG•Passage Bio shareholders approved merger-related share issuance, a reverse stock split of 1-for-2 to 1-for-10, a charter restatement and two equity plans at a November 5, 2026, special meeting.
1. Shareholder approvals
Passage Bio shareholders approved issuing shares to Remix Therapeutics securityholders in connection with a merger. They also authorized a reverse stock split ranging from 1-for-2 to 1-for-10, with the final ratio subject to mutual agreement.
2. Charter and equity plans
Stockholders approved a restated charter that includes changing the company’s name to Remix Therapeutics when the second merger becomes effective. They also approved nonbinding charter proposals on the name change, voting requirements and other governance provisions, and adopted the 2026 Equity Incentive Plan and Employee Stock Purchase Plan, effective upon completion of the first merger.
